Cargando…

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma

Lenalidomide is an oral immunomodulatory drug that has helped improve outcomes in multiple myeloma (MM) patients. Combination lenalidomide and dexamethasone (Len+Dex) has been shown to increase response rates and prolong survival compared with dexamethasone alone in patients with relapsed or refract...

Descripción completa

Detalles Bibliográficos
Autores principales: Alegre, Adrian, Vicuña, Isabel, Aguado, Beatriz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256976/
https://www.ncbi.nlm.nih.gov/pubmed/22253550
http://dx.doi.org/10.4137/CMO.S7275
_version_ 1782221085644685312
author Alegre, Adrian
Vicuña, Isabel
Aguado, Beatriz
author_facet Alegre, Adrian
Vicuña, Isabel
Aguado, Beatriz
author_sort Alegre, Adrian
collection PubMed
description Lenalidomide is an oral immunomodulatory drug that has helped improve outcomes in multiple myeloma (MM) patients. Combination lenalidomide and dexamethasone (Len+Dex) has been shown to increase response rates and prolong survival compared with dexamethasone alone in patients with relapsed or refractory MM (RRMM). Clinical benefit may be greatest when Len+Dex is given at first relapse, and continued treatment appears to provide greater depth of response and improved survival outcomes. The most common adverse events associated with Len+Dex are cytopenias, which are predictable and manageable. Len+Dex is associated with an increased risk of venous thromboembolism, which necessitates adequate prophylaxis. The risk of second primary malignancies does not appear to be increased in patients with RRMM treated with lenalidomide-based therapy. Here we review the safety and efficacy of Len+Dex in RRMM, and provide an overview of data from Spain on the use of Len+Dex in RRMM.
format Online
Article
Text
id pubmed-3256976
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-32569762012-01-17 Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma Alegre, Adrian Vicuña, Isabel Aguado, Beatriz Clin Med Insights Oncol Review Lenalidomide is an oral immunomodulatory drug that has helped improve outcomes in multiple myeloma (MM) patients. Combination lenalidomide and dexamethasone (Len+Dex) has been shown to increase response rates and prolong survival compared with dexamethasone alone in patients with relapsed or refractory MM (RRMM). Clinical benefit may be greatest when Len+Dex is given at first relapse, and continued treatment appears to provide greater depth of response and improved survival outcomes. The most common adverse events associated with Len+Dex are cytopenias, which are predictable and manageable. Len+Dex is associated with an increased risk of venous thromboembolism, which necessitates adequate prophylaxis. The risk of second primary malignancies does not appear to be increased in patients with RRMM treated with lenalidomide-based therapy. Here we review the safety and efficacy of Len+Dex in RRMM, and provide an overview of data from Spain on the use of Len+Dex in RRMM. Libertas Academica 2011-12-06 /pmc/articles/PMC3256976/ /pubmed/22253550 http://dx.doi.org/10.4137/CMO.S7275 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Review
Alegre, Adrian
Vicuña, Isabel
Aguado, Beatriz
Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
title Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
title_full Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
title_fullStr Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
title_full_unstemmed Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
title_short Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
title_sort safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256976/
https://www.ncbi.nlm.nih.gov/pubmed/22253550
http://dx.doi.org/10.4137/CMO.S7275
work_keys_str_mv AT alegreadrian safetyandefficacyoflenalidomideinrelapsedorrefractorymultiplemyeloma
AT vicunaisabel safetyandefficacyoflenalidomideinrelapsedorrefractorymultiplemyeloma
AT aguadobeatriz safetyandefficacyoflenalidomideinrelapsedorrefractorymultiplemyeloma